Paolo Tarantino: Final analysis of the PEONY phase 3 trial

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Final analysis of the PEONY phase 3 trial published on Nature Communications. Among 329 Asian patients with HER2+ BC, the addition of pertuzumab to perioperative treatment led to meaningful improvement in 5-year EFS (Δ11.1%), with benefit both in patients with pathologic complete response (pCR) and RD. ”

Source: Paolo Tarantino/X